Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 14/20 | 0.61 |
| ▸ | PARP1 | P09874 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9725333 | 0.81 | DHODH (0.77) | DHODHPARP1KDM4E | |
| SCHEMBL2310564 | 0.81 | MGAM (0.62) | — | |
| SCHEMBL506401 | 0.80 | DHODH (0.59) | DHODHPARP1KDM4ERAB9A | |
| SCHEMBL1298432 | 0.79 | DHODH (0.94) | DHODHPARP1 | |
| SCHEMBL1889612 | 0.78 | PARP1 (0.80) | DHODHPARP1KDM4ERAB9A | |
| SCHEMBL2314062 | 0.77 | NPC1 (0.57) | ALDH1A1L3MBTL1KDM4ERAB9A | |
| SCHEMBL1889016 | 0.76 | DHODH (0.59) | DHODHPARP1 | |
| SCHEMBL2310248 | 0.76 | PARP1 (0.47) | DHODHPARP1ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL1298094 | 0.76 | DHODH (0.61) | DHODHPARP1KDM4E | |
| SCHEMBL505661 | 0.76 | DHODH (1.00) | DHODHPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | HSP90B1, HSP90AB1, HSP90AA1 | DHODH 3140/4885PARP1 2606/4885ALDH1A1 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.